Supplier Related Products Identification Chemical Properties Safety Data Raw materials And Preparation Products Hazard Information Material Safety Data Sheet(MSDS) Spectrum Detail Well-known Reagent Company Product Information
WebSite >  CAS DataBase List  > 58-55-9

58-55-9

Supplier Related Products Identification Chemical Properties Safety Data Raw materials And Preparation Products Hazard Information Material Safety Data Sheet(MSDS) Spectrum Detail Well-known Reagent Company Product Information

Product Image

Identification

Name
Theophylline
CAS
58-55-9
Synonyms
1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDROPURINE
1,3-DIMETHYL-7H-PURINE-2,6-DIONE
2,6-DIHYDROXY-1,3-DIMETHYLPURINE
3,7-DIHYDRO-1,3-DIMETHYL-1H-PURINE-2,6-DIONE
CAFFEINE IMP A
ELIXOPHYLLINE
LABOTEST-BB LT00000171
THEOPHYLINE
THEOPHYLLINE
THEOPHYLLINE BASE
1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3-dimethyl-xanthin
1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-
3,7-dihydro-1,3-dimethyl-1h-purine-6-dione
3h)-dione,1,3-dimethyl-purine-6(1h
6-dione,3,7-dihydro-1,3-dimethyl-1H-Purine-2
accurbron
Acet-theocin
aerolate
Aerolate III
EINECS(EC#)
200-385-7
Molecular Formula
C7H8N4O2
MDL Number
MFCD00079619
Molecular Weight
180.16
MOL File
58-55-9.mol

Chemical Properties

Appearance
white to light yellow crystal powder
Melting point 
271-273 °C

mp 
271-273 °C

Boiling point 
312.97°C (rough estimate)
density 
1.3640 (rough estimate)
refractive index 
1.6700 (estimate)
Fp 
11 °C
storage temp. 
2-8°C

solubility 
0.1 M HCl: soluble

pka
8.77(at 25℃)
form 
powder

color 
white

Stability:
Stable. Incompatible with strong oxidizing agents.
Water Solubility 
8.3 g/L (20 ºC)
Merck 
9285
BRN 
13463
InChIKey
ZFXYFBGIUFBOJW-UHFFFAOYSA-N
Uses
theophylline is tonic and skin conditioning. Its cosmetic activity is not clearly or definitively established. It is most often found in anti-cellulite products. Theophylline is in the same family of bio chemicals as caffeine. It is naturally occurring in tea.
CAS DataBase Reference
58-55-9(CAS DataBase Reference)
NIST Chemistry Reference
1,3-Dimethylxanthine(58-55-9)
IARC
3 (Vol. 51) 1991
EPA Substance Registry System
58-55-9(EPA Substance)

Safety Data

Hazard Codes 
Xn,T,F,Xi
Risk Statements 
R22:Harmful if swallowed.
R39/23/24/25:Toxic: danger of very serious irreversible effects through inhalation, in contact with skin and if swallowed .
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed .
R11:Highly Flammable.
R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Statements 
S7:Keep container tightly closed .
S16:Keep away from sources of ignition-No smoking .
S36/37:Wear suitable protective clothing and gloves .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
RIDADR 
UN 2811 6.1/PG 3

WGK Germany 
1

RTECS 
XH3850000


10-23
TSCA 
Yes
HazardClass 
6.1(b)
PackingGroup 
III
HS Code 
29399900
Safety Profile
Human poison by ingestion, parenteral, intravenous, and rectal routes. Experimental poison by multiple routes. An experimental teratogen. Human systemic effects: coma, convulsions or effect on seizure threshold, cyanosis, EKG changes, fever and other metabolic effects, heart arrhythmias, heart rate change, hyperglycemia, metabolic acidosis, nausea or vomiting, potassium-level changes, respiratory stimulation, salivary gland changes, somnolence, tremor. Experimental reproductive effects. Human mutation data reported. Used as a dturetic, cardtac stimulant, smooth muscle relaxant, and to treat asthma. When heated to decomposition it emits toxic fumes of NOx.
Hazardous Substances Data
58-55-9(Hazardous Substances Data)
Toxicity
LD50 oral in rabbit: 350mg/kg

Raw materials And Preparation Products

Hazard Information

General Description
Odorless white crystalline powder. Odorless. Bitter taste.
Reactivity Profile
THEOPHYLLINE(58-55-9) neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen may be generated in combination with strong reducing agents, such as hydrides.
Air & Water Reactions
Slightly soluble in water.
Fire Hazard
Flash point data for this chemical are not available, however THEOPHYLLINE is probably combustible.
Description
Dosing requires the determination of plasma levels with 10 to 20 μg/mL being associated with the least incidence of side effects. Overdose of theophylline can result in a quick onset of ventricular arrhythmias, convulsions, or even death without any previous warning. Many drugs increase the plasma concentration of theophylline, including quinolone and macrolide antibiotics, nonselective β-blockers, ephedrine, calcium channel blockers, cimetidine, and oral contraceptives. Theophylline is available in tablet, capsule, liquid, and parenteral dosage preparations. There also are combination products with guaifenesin and ephedrine available as tablet and liquid dosage forms. There are two products that are theophylline salts. Aminophylline is theophylline ethylenediamine, which contains 70% theophylline and is available in tablets, liquid, parenteral, and suppository dosage forms. Oxytriphylline is the choline salt of theophylline, and it contains 64% theophylline in tablets and liquid dosage forms. Care must be taken to correctly calculate the equivalent dose when switching a patient from theophylline to one of its salts.
Chemical Properties
white to light yellow crystal powder
Physical properties
Appearance: white, crystalline powder, odorless, with a bitter taste. Solubility: freely soluble in solutions of alkali hydroxides and in ammonia; sparingly soluble in alcohol, in chloroform, and in ether; slightly soluble in water. Water solubility, 7.36?g/L (20?°C); density, 1.62?g/cm3 ; melting point, 270–274?°C; boiling point, 390.1?°C (760? mmHg); flash point, 189.7?°C; vapor pressure, 2.72E-06? mmHg (25?°C).
History
Theophylline was firstly extracted from tea leaves and chemically identified by the German biologist Albrecht Kossel. A cup of tea contains about 1?mg/mL theophylline. In 1895, a chemical synthesis of theophylline starting with 1,3-dimethyluric acid was described by Emil Fischer and Lorenz Ach. Theophylline was synthesized by Wilhelm Traube in 1900. Aminophylline, a derivative of theophylline ethylenediamine, is widely used due to its greater aqueous solubility.
Theophylline was firstly used clinically as a diuretic in 1902. Twenty years later it was firstly reported by D.I.?Macht and G.C.?Ting for asthma treatment in pig bronchial smooth muscle. The first successful clinical use of theophylline in bronchial asthma was reported in 1922 by S.? Hirsch, who described that four patients responded well to the rectal administration of a mixture of 66.7% theophylline and 33.3% theobromine. He also tested the combination of theophylline with theobromine on bovine bronchial smooth muscle strips and noted smooth muscle relaxation. Thus he concluded that dimethylxanthines act by producing relaxation of bronchial smooth muscle. In 1937, two concurrent but independent clinical trials reported that methylxanthines were efficacious in asthma. The Food and Drug Administration approved the use of theophylline for asthma in the USA in 1940.
There are more than 300 derivatives of theophylline. The main derivatives include aminophylline, dihydroxypropyl theophylline, and oxtriphylline.
2. Doxofylline: 7-(1,3-dioxalan-2-ylmethyl) theophylline. It has antitussive and bronchodilator effects. In animal and human studies, it has shown similar efficacy to theophylline but with fewer side effects. Related research has showed that the effect of doxofylline on airway relaxation is 10–15 times that of aminophylline.
3. Diprophylline: 7-(2,3-dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine- 2,6-dione. Diprophylline is the neutral preparation of theophylline. It causes less of nausea and gastric irritation.
4. Oxtriphylline: choline theophyllinate; administered orally. Oxtriphylline is five times more soluble than aminophylline.

Indications
Twenty years ago theophylline (Theo-Dur, Slo-bid, Uniphyl, Theo-24) and its more soluble ethylenediamine salt, aminophylline, were the bronchodilators of choice in the United States. Although the β2-adrenoceptor agonists now fill this primary role, theophylline continues to have an important place in the therapy of asthma because it appears to have antiinflammatory as well as bronchodilator activity.
Definition
ChEBI: A dimethylxanthine having the two methyl groups located at positions 1 and 3. It is structurally similar to caffeine and is found in green and black tea.
Hazard
Questionable carcinogen.
Biological Activity
Bronchodilator, anti-inflammatory and immunomodulator. Antagonizes adenosine receptors and is a weak non-selective inhibitor of phosphodiesterases (PDEs).
Mechanism of action
In spite of a great deal of investigation, just how theophylline causes bronchodilation is not clearly understood. Inhibition of the enzyme PDE, which is responsible for the hydrolysis of cAMP and cyclic guanosine monophosphate (cGMP), generally is put forth as the mechanism of action; however, theophylline also is an adenosine antagonist and has been implicated in stimulation of the release of catecholamines. It has been clearly shown that theophylline does inhibit PDEs in vitro, and x-ray crystallographic studies have identified the binding residues that interact with the methylxanthines. Theophylline binds to a subpocket of the active site and appears to be sandwiched between a phenylalanine and a valine via hydrophobic bonds. Its binding affinity is reinforced by hydrogenbonding between a tyrosine and N-7 and a glutamine and O-6 of the xanthine ring system. There are more than 11 families of PDEs, and studies have shown that theophylline binds in a similar manner to both the PDE4 and PDE5 family isoforms.
Pharmacology
Smooth muscle relaxation, central nervous system (CNS) excitation, and cardiac stimulation are the principal pharmacological effects observed in patients treated with theophylline.The action of theophylline on the respiratory system is easily seen in the asthmatic by the resolution of obstruction and improvement in pulmonary function. Other mechanisms that may contribute to the action of theophylline in asthma include antagonism of adenosine, inhibition of mediator release, increased sympathetic activity, alteration in immune cell function, and reduction in respiratory muscle fatigue. Theophylline also may exert an antiinflammatory effect through its ability to modulate inflammatory mediator release and immune cell function.
Inhibition of cyclic nucleotide phosphodiesterases is widely accepted as the predominant mechanism by which theophylline produces bronchodilation. Phosphodiesterases are enzymes that inactivate cAMP and cyclic guanosine monophosphate (GMP), second messengers that mediate bronchial smooth muscle relaxation.
Clinical Use
The principal use of theophylline is in the management of asthma. It is also used to treat the reversible component of airway obstruction associated with chronic obstructive pulmonary disease and to relieve dyspnea associated with pulmonary edema that develops from congestive heart failure.
Side effects
Theophylline has a narrow therapeutic index and produces side effects that can be severe, even life threatening. Importantly, the plasma concentration of theophylline cannot be predicted reliably from the dose. In one study, the oral dosage of theophylline required to produce therapeutic plasma levels (i.e., between 10 and 20 μg/mL) varied between 400 and 3,200 mg/day. Heterogeneity among individuals in the rate at which they metabolize theophylline appears to be the principal factor responsible for the variability in plasma levels. Such conditions as heart failure, liver disease, and severe respiratory obstruction will slow the metabolism of theophylline.
Chemical Synthesis
Theophylline, 1,3-dimethylxanthine (23.3.5), is present in small quantities in tea leaves. It is synthesized synthetically by the Traube method, a general method suggested for making purine bases. In the given example, reacting N,N-dimethylurea with cyanoacetic ether in the presence of acetic anhydride gives cyanoacetylmethylurea (23.3.1), which cyclizes into 6-amino-1,3-dimethyluracil (23.3.2). The resulting compound transforms into 5-nitroso-6-amino-1,3-dimethyluracil (23.3.3) upon reaction with nitric acid. Reduction of the nitroso group gives 5,6-diamino-1,3-dimethyluracil (23.3.4), the subsequent reaction of which with formamide gives the desired theophylline (23.3.5).


Environmental Fate
Theophylline is readily broken down in the environment. It may undergo photolytic degradation in the air or when exposed to light. In moist soil, or aqueous environments, it undergoes rapid biodegradation.
Metabolism
Chemically, theophylline is 1,3-dimethylxanthine and contains both an acidic and a basic nitrogen (N-7 and N-9, respectively). Physiologically, it behaves as an acid (pKa = 8.6), and its poor aqueous solubility can be enhanced by salt formation with organic bases. Theophylline is metabolized by a combination of C-8 oxidation and N-demethylation to yield methyluric acid metabolites. The major urinary metabolite is 1,3-dimethyl uric acid, which is the product of the action of xanthine oxidase. Because none of the metabolites is uric acid itself, theophylline can be safely given to patients who suffer from gout.
Purification Methods
It crystallises from H2O as the monohydrate which becomes anhydrous above 100o. It is freely soluble in hot H2O, but its solubility at 15o is 0.44%. It complexes with heavy metals. It is a diuretic, vasodilator and a cardiac stimulant. [Lister Purines Part II, Fused Pyrimidines Brown Ed, Wiley-Interscience pp253-254 1971, ISBN 0-471-38205-1, Beilstein 26 H 455, 26 I 134, 26 II 263, 26 III/IV 2331.]
Toxicity evaluation
The mechanism of action is multifactorial. Suggested theories of action include increased cellular cyclic adenosine monophosphate levels via inhibition of phosphodiesterase, increased turnover of monoamines in the central nervous system (CNS),inhibition of prostaglandins, and antagonism of adenosine receptors. Overall, these mechanisms contribute to an increase in catecholamine release. In acute overdoses, theophylline often causes severe emesis (75% in acute vs 30% in chronic). The emesis is often difficult to control with antiemetics. It is thought that theophylline causes increased gastric acid secretion and smooth muscle relaxation. Theophylline causes a release of endogenous catecholamines, and therefore is a cardiac stimulant. There is a positive inotropic and dose-dependent chronotropic response. Tachydysrhythmias, especially supraventricular tachycardia, are common due to adenosine receptor antagonism. Ventricular tachydysrhythmias can occur as well in acute overdose; however, they are rare at therapeutic concentrations. Rapid administration of aminophylline has resulted in sudden cardiac death. Hypokalemia, hypercalcemia, and hyperglycemia may contribute to arrhythmias as well. In cases of chronic toxicity, dysrhythmias occur at lower serum concentrations (40–80 mg ml-1) compared to acute overdose. Theophylline will stimulate the CNS respiratory center causing increased respiratory rate and can lead to respiratory alkalosis. Theophylline will cause CNS stimulation and vasoconstriction, similar to caffeine, and may lead to headache, anxiety, agitation, insomnia, tremor, irritability, hallucinations, and seizures. Methylxanthines exhibit weak diuretic effects by increasing cardiac output and renal vasodilation. Theophylline has a narrow therapeutic index, with 12–25% of overdose patients developing serious or life-threatening symptoms including arrhythmias and seizure. Toxicity can develop at lower serum concentrations for those treated chronically or older patients. Age greater than 60 years and chronic use are risk factors for increased morbidity and mortality.
Precautions
Theophylline should be used with caution in patientswith myocardial disease, liver disease, and acutemyocardial infarction. The half-life of theophylline isprolonged in patients with congestive heart failure.Because of its narrow margin of safety, extreme cautionis warranted when coadministering drugs, such as cimetidineor zileuton, that may interfere with the metabolismof theophylline. Indeed, coadministration of zileutonwith theophylline is contraindicated. It is alsoprudent to be careful when using theophylline in patientswith a history of seizures.
References
Fischer., Ber., 30, 553 (1897)
Schwabe., Arch. Pharm., 245, 312 (1907)
Biltz, Strufe.,Annalen, 404, 137, 170(1914)
Yoshitomi., Chem. Abstr., 19,2303 (1925)
Mossini., Boll. chim. farm., 75, 557 (1936)
Deichmeister., Farm. Zhur., 13, 18 (1940)
Deichmeister., Chem. Zentr., 1, 1280 (1942)
Deniges., Bull. trav. soc. ph arm. Bordeaux, 79, 141 (1941)
Lesser., Drug & Cosmetic Ind., 66, 276,340 (1950)

Material Safety Data Sheet(MSDS)

Spectrum Detail

Well-known Reagent Company Product Information

SupplierMore